pharmaphorum

MAY 12, 2022

AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve clinical remission over a full year when used as a maintenance therapy. ” For AbbVie, the results could unlock sales of $1.3 ” For AbbVie, the results could unlock sales of $1.3

FDA 65

FDA Hospitals 65

Med Ed 101

JULY 17, 2019

This guest post on comparing Crohn’s disease and Ulcerative Colitis was contributed by pharmacist Jiamin Liau who is also a Certified Diabetes Educator in Australia. The post Comparing Crohn’s Disease and Ulcerative Colitis appeared first on Med Ed 101.

40

40

Pharmaceutical Technology

JANUARY 31, 2023

The company is seeking regulatory approval of Hyrimoz for several indications, including ulcerative colitis, plaque psoriasis, rheumatoid arthritis, Crohn’s disease, and uveitis, covered by the reference medicine.

Packaging 64

Packaging 64

European Pharmaceutical Review

JANUARY 30, 2023

The authorisation includes all indications covered by the reference medicine Humira ® : rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis and uveitis. By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases.

Packaging 73

Packaging FDA 73

pharmaphorum

DECEMBER 22, 2022

Regulators in the US and EU have started a review of Pfizer’s S1P receptor modulator etrasimod for people living with moderately-to-severely active ulcerative colitis (UC), with decisions expected in the first halves of 2023 and 2024, respectively.

FDA 52

FDA 52

pharmaphorum

MAY 25, 2022

billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals’ etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble seems to have paid off. Pfizer placed a $6.7

59

59

European Pharmaceutical Review

FEBRUARY 2, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved RINVOQ ® ▼ (upadacitinib), the first oral advanced therapy for adults with moderately to severely active Crohn’s disease (CD). The MHRA’s approval in CD follows upadacitinib’s approval in ulcerative colitis (UC) last year.

Hospitals 64

Hospitals 64

The Checkup by Singlecare

DECEMBER 15, 2022

Compare Remicade alternatives | Renflexis | Humira | Stelara | Xeljanz XR | Trexall | Natural alternatives | How to switch meds. Remicade is also FDA approved for use in pediatric patients ages six and older for the treatment of Crohn’s and ulcerative colitis. . In fact, they pop up in commercials frequently.

Immunization 52

Immunization Dosage Labelling FDA 52

Pharmaceutical Technology

FEBRUARY 24, 2023

As the Crohn’s disease (CD) therapeutic landscape grows crowded with added therapies, the success of new agents entering the market depends on their ability to show distinction from comparable first-in-class drugs. In the current standard-of-care treatment algorithm, JAKis or biologics are third-line options following anti-TNFs.

59

59

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.

FDA 52

FDA Labelling 52

PharmaShots

JUNE 27, 2023

ACR20/50/70 responses and mean change in DAS28-ESR and DAS28-CRP from baseline were comparable across the three treatment groups. How was the ACR’22 experience for biosimilars for Biogen? Smriti: Can we talk about BIIB800, a tocilizumab biosimilar? The trial met its primary endpoints of ACR20* response at Week 12 and Week 24.

Immunization 40

Immunization FDA 40

Hospital Pharmacy Europe

OCTOBER 9, 2023

This brief pilot study report details a small retrospective study undertaken in a UK hospital that looked at the implications of removing prior authorisation (Blueteq) for the biosimilars adalimumab or infliximab when used in inflammatory bowel disease. 1 ​Remission can be determined as either clinical or endoscopic.

Hospitals 52

Hospitals Documentation 52

The Thyroid Pharmacist

OCTOBER 28, 2022

When I was searching for answers on how to get my Hashimoto’s into remission and feel like myself again after so many years of frustrating symptoms, I started by analyzing my health timeline, and then investing in functional medicine testing. When the gut barrier is impaired, these harmful organisms can leak into the body.

Health and Personal Care Stores 105

Health and Personal Care Stores Immunization Grocery Stores Compounding 105

PharmaShots

APRIL 5, 2023

neovascular (wet) AMD Additionally, the availability of Byooviz could enable more patients to access this type of vision-saving therapy as it brings a sustainable and cost-effective anti-VEGF treatment to Canadian vision care Byooviz was approved in Canada for the treatment of multiple eye disorders.

FDA 49

FDA Packaging Labelling Patient Care 49